CClinicalTrials.gg
TerminatedNCT03761823Updated Apr 11, 2024

Post-extubation Dysphagia

An observational study in Post-extubation Dysphagia, sponsored by Radboud University Medical Center. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Radboud University Medical Center · Observational

Why this study was terminated
Organizational issues and slow inclusion rate
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5
Ages
18 Years and older
Sex
All
01

Study summary

Mechanical ventilation is a widely used treatment on the Intensive Care Unit (ICU). Swallowing dysfunction (dysphagia) after extubation may cause aspiration, and is associated with poor outcomes: pneumonia, reintubation, a prolonged length of hospital stay and increased mortality. The exact underlying pathophysiology of post-extubation dysphagia (PED) is unknown. This exploratory pilot study is the first step that aims to fill this knowledge gap to ultimately improve current treatment and prevention of post-extubation dysphagia.

Using FEES (Flexible Endoscopic Evaluation of Swallowing), HRIM (High Resolution Impedance Manometry) and EMG (electromyography) simultaneously, 5 healthy subjects and 25 patients within 24 hours after extubation will be studied.

Read the detailed description

Observational study model:

The group of healthy subjects will be recruited using posters at the local university and the internet. The healthy subjects will be studied before the group of patients to assess the feasibility and possible interactions of simultaneously recording FEES, HRIM and EMG. Then, the group of patients will be studied. They will be recruited from the Intensive Care Unit. See In- and Exclusion criteria for details.

02

Conditions studied

  • Post-extubation Dysphagia

Browse trials for

Keywords

  • Flexible endoscopic evaluation of swallowing
  • High resolution impedance manometry
  • Electromyography
  • Intensive Care Unit
03

In context

Deglutition Disorders

710 studies on the registry are indexed under Deglutition Disorders; 219 are open to participants now.

This study's enrollment of 5 is below the median of 97 across 207 observational studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy subjects will be recruited using posters at the local university and the internet.

Intensive care patients that will be extubated shortly.

Eligibility criteria

Inclusion Criteria (patients):

  • age > 18 years
  • informed consent
  • extubated after endotracheal intubation for more than 5 days
  • Richmond Agitation-Sedation Scale (RASS) between -2 and 2
  • able to sit right up
  • no respiratory insufficiency/failure (for this study defined as oxygen saturation (SpO2) \< 92% with a minimum of 3 L nasal oxygen)

Inclusion Criteria (healthy subjects):

  • age > 18 years
  • informed consent

Exclusion Criteria (both patients and healthy subjects):

  • pre-existing dysphagia (according to medical record and screening)
  • tracheostomy or previous tracheostomy
  • history of prior intubation \< 3 months ago
  • head/neck surgery, head/neck radiation or head/neck disease
  • pre-existent esophageal disorder
  • coagulopathy (thrombocytes \< 50*10\^9 /l, or prothrombin time (PT)/activated partial thromboplastin time (APTT) > 1.5 times the reference value, or fibrinogen \< 1000 mg/l, or use of therapeutic anticoagulant drugs)
  • allergy for xylometazoline (only in case its use is indicated)
  • known pregnancy
  • known G6PD deficiency
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy subjects

    Healthy subjects

  • Patients

    Patients extubated after \> 5 days of mechanical ventilation.

06

What researchers measure

Primary outcomes

  1. The number of patients with aspiration during FEES will be assessed.

    Time frame: At time of measurement (within 24 hours post-extubation)

Secondary outcomes

  1. Pathophysiology of PED

    The pathophysiology of PED will be determined after simultaneous measurement of FEES, HRIM and EMG. The pathophysiology will be classified into several categories: reduced pharyngeal contractility / muscular weakness, reduced upper esophageal sphincter (UES) opening/relaxation, direct oropharyngeal or laryngeal trauma of the tube, reduced laryngeal sensibility, among other categories. To enable classification, parameters obtained from FEES, HRIM and EMG will be used. FEES: presence of penetration and aspiration, residue, reduced sensibility (among others); HRIM: pharyngeal peak pressure, UES maximum admittance, intrabolus pressure (among others); EMG: duration of muscle activity (among others).

    Time frame: At time of measurement (within 24 hours post-extubation)

  2. The number of adverse events will be assessed.

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  3. Interaction of FEES on HRIM recording

    HRIM outcomes during the simultaneous recording will be compared with outcomes of recording with only HRIM in situ.

    Time frame: At time of measurement (within 24 hours post-extubation)

  4. Correlation of FEES with HRIM

    The correlation of FEES outcomes, e.g. PAS and residue, with HRIM outcomes, e.g. swallow risk index and post-swallow impedance ratio.

    Time frame: At time of measurement (within 24 hours post-extubation)

Other outcomes

  1. The number of patients that develop pneumonia will be assessed.

    Pneumonia is defined according to the Center of Disease Control criteria.

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  2. Reintubation rate (dysphagia vs. non-dysphagia)

    The number of patients that are reintubated during their hospital stay will be assessed.

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  3. ICU readmission rate (dysphagia vs. non-dysphagia)

    The number of patients that are readmitted to the ICU during their hospital stay will be assessed.

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  4. Length of ICU stay (dysphagia vs. non-dysphagia)

    Length of ICU stay will be assessed (in days).

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  5. Length of hospital stay (dysphagia vs. non-dysphagia)

    Length of hospital stay will be assessed (in days).

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  6. ICU mortality (dysphagia vs. non-dysphagia)

    The incidence of mortality during ICU stay will be assessed.

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

  7. Hospital mortality (dysphagia vs. non-dysphagia)

    The incidence of mortality during hospital stay will be assessed.

    Time frame: Participants will be followed until hospital discharge, an expected average of 28 days

07

Study locations

1 site
  • Radboudumc
    Nijmegen, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03761823
Lead sponsor
Radboud University Medical Center
Responsible party
Sponsor
First posted
Dec 3, 2018
Start date
Jan 22, 2019
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019
Last update
Apr 11, 2024

Study contacts

Johannes G. van der Hoeven, prof. dr.
principal investigator · Radboud University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion